Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsA Perspective of Immunotherapy for Prostate CancerCAR models: next-generation CAR modifications for enhanced T-cell functionChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesMesothelin-Targeted CARs: Driving T Cells to Solid TumorsAdoptive T-cell therapy for cancer: The era of engineered T cellsCAR T cells for solid tumors: armed and ready to go?T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectCARs in chronic lymphocytic leukemia -- ready to driveDeveloping strategies in the immunotherapy of leukemiasAdoptive cell therapy for sarcomaImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaCAR therapy: the CD19 paradigmCombining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaB-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsEngineered T cells for cancer treatmentCaspase-9: structure, mechanisms and clinical applicationStrategies to genetically engineer T cells for cancer immunotherapy.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancerConsiderations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.Novel roles for IL-15 in T cell survivalImproving the safety of cell therapy products by suicide gene transferImproving the safety of cell therapy with the TK-suicide geneGenetic modification of T cellsT cells redirected against CD70 for the immunotherapy of CD70-positive malignanciesAntigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Survivin-specific T cell receptor targets tumor but not T cells.Engager T cells: a new class of antigen-specific T cells that redirect bystander T cellsGene therapy for cancer: present status and future perspectiveTumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugsSeatbelts in CAR therapy: How Safe Are CARS?Genetically modified T-cell therapy for osteosarcoma
P2860
Q26741260-DB52794D-A85C-4C35-9ABE-558092AB59E9Q26741277-AF8BBE9B-A3A0-4792-8E11-03279715F1D8Q26745600-BB34B9E8-07C6-4F14-ADFB-94A1B838339AQ26753082-F2CF1925-5910-426F-94EC-AE5A1264FF70Q26773309-D3E2E8A0-99BE-4C98-9423-3BCE91093B85Q26775720-0AAD6FC8-95E0-48D4-8A84-26964D8F4DAFQ26778759-16440BCD-081E-4E4F-89A4-00DC05EEBB67Q26800611-08F14029-AD24-4963-B90A-C5620545CBFCQ26825489-25FABBB5-013C-43D5-8D49-B2E0ED0AAD07Q26826830-FC6A8020-BD14-4CC0-BB78-1DE89E7D27D7Q26830526-5C8C98F0-DD41-4CAF-A178-E2DF9B540DF7Q26996310-21BF7BF1-048D-48B3-AF59-FABDAE38875FQ27009541-1C3C954A-F817-4A9D-BCC1-B9103F1B44C3Q28068378-A9C5A9BD-072C-454A-9E1A-6554AF498D1BQ28079823-47CC1434-9AF7-4985-9F71-4C91A4D0F556Q28081600-C64987A5-AE05-4662-9582-9BBD57753F02Q28081642-1D51617F-7164-48E7-8C16-60214BF41911Q28537688-562196E7-E3C0-44BC-BD3B-B62E1FFA0259Q29620717-26975776-8771-4DDA-9A81-E481B0B309E3Q33578792-F340D2BA-6A25-4B8C-B611-1AA159B1A48BQ33618946-9B5A3292-176F-436B-9775-9AC719E55FE9Q33655849-05C1FF7F-7502-4DC2-8B1E-9941B7C0F76CQ33993529-398A0BFF-40B0-4EF4-8E18-C4A591968C27Q34025234-EE8D7042-828F-472B-9731-5DCB6FB9DD06Q34122292-36ED453F-1CD5-4AEA-9FEA-1DEDF47FB8D8Q34163218-92497E21-BFF6-4615-93C7-32BFB1AE6E3DQ34205181-63D2DA01-1B44-466E-AA8D-0077C5CCCB48Q34270375-30ADC2BB-F943-47E5-AC09-28A12FFE6432Q34344246-1A29CA46-2F44-4519-A558-73EE057AD1DBQ34453846-4CCF9CDD-A50B-4E29-8170-5FDF9BE39396Q34477411-1F95476F-C873-4A68-B9F7-95C21DA92D8CQ34644876-E3F318A6-52B3-4B7D-A726-9A609378F810Q34923799-CE6DD905-AD5A-490B-AC76-B932E10C2360Q35034803-7181BACF-091C-48A6-9E9C-E4264B9426C7Q35242576-32D5BCF6-5E4B-4398-B769-E4B0A5A67A1AQ35591391-64A345ED-6D5F-4F35-BCE4-9DB3D06BA699Q35673900-7C851F75-4BBC-4F3E-84AC-0E1ECCE29CFBQ35757397-9E4B42D6-F468-4B56-A99D-D4B16E59EB3DQ35818365-4E5D0C5A-9388-4B68-BA85-6A7CE81BEBA1Q36198232-1000D56A-B00D-4998-A3B7-4DA66ECC3DC6
P2860
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Engineering CD19-specific T ly ...... a/leukemia effects and safety.
@en
type
label
Engineering CD19-specific T ly ...... a/leukemia effects and safety.
@en
prefLabel
Engineering CD19-specific T ly ...... a/leukemia effects and safety.
@en
P2093
P2860
P356
P1433
P1476
Engineering CD19-specific T ly ...... a/leukemia effects and safety.
@en
P2093
A Mahendravada
C M Rooney
C Quintarelli
H E Heslop
M K Brenner
P2860
P2888
P304
P356
10.1038/LEU.2010.75
P577
2010-04-29T00:00:00Z
P5875
P6179
1046548342